outcomes

Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003.
Researchers from Yale and a few other centers analyzed data from the vast NHANES nutritional and medical survey, done
ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles